Skip to content
All Sections
Subscribe Now
73°F
Wednesday, August 28th 2024
e-Edition
Home Page
Close Menu
News
News
Crime and Public Safety
Investigative Reporting
Politics
Health
Environment
Business
Best Reviews
Housing
Jobs
Local News
Local News
Long Beach
Los Angeles
Los Angeles County
Sports
Sports
High School Sports
Chargers
Rams
Lakers
Clippers
Dodgers
Angels
College Sports
UCLA Sports
USC Sports
Long Beach State sports
Kings
Ducks
Olympics
Boxing/MMA
Soccer
Horse Racing
Things To Do
Things To Do
Restaurants Food and Drink
Movies
Music + Concerts
Theater
TV and Streaming
Home + Garden
Travel
Amusement Parks
Comics
Puzzles
Events
Obituaries
Obituaries
News Obituaries
Place an Obituary
Opinion
Opinion
Editorials
Opinion Columns
Commentary
Letters to the Editor
Editorial Board
Endorsements
The Grunion
The Grunion
News
Education
Sports
Things to Do
Opinion
E-Edition
Advertising
Contact Us
SCNG Premium
The T.E.A.
Subscribe
Press-Telegram Store
Log In
Logout
Close Menu
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Account Settings
Contact Us
Log Out
Spoof a user
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Search
Press Telegram
73°F
Wednesday, August 28th 2024
e-Edition
News
Local News
Sports
Things to Do
Obituaries
Opinion
The T.E.A.
Trending:
High School Football
New Metro Line funding
No contest plea in fatal shooting
Homeless man fatally shot
Michelin-starred chef's new restaurant
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Vistagen
< Previous
1
2
Next >
Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update
August 13, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024
August 06, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine
July 09, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year
June 27, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
June 11, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024
June 07, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present at the Jefferies Global Healthcare Conference
May 29, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference
May 23, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference
May 07, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
April 25, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
April 09, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
April 01, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present at Stifel 2024 Virtual CNS Days
March 11, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present at TD Cowen 44th Annual Health Care Conference
February 28, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update
February 13, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024
February 06, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain
December 27, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results
November 09, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present at Stifel 2023 Healthcare Conference
November 08, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences
November 07, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen To Report Second Quarter Financial Results and Host Corporate Update Conference Call on November 9, 2023
November 06, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
October 05, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
September 12, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagen’s Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan
September 05, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Appoints Cindy Anderson as Chief Financial Officer
August 22, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Subsequent to the Release of Positive Phase 3 Trial Results, Vistagen Provides Corporate Update and Reports Fiscal 2024 First Quarter Financial Results
August 10, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen To Report First Quarter Financial Results and Host Corporate Update Conference Call on August 10, 2023
August 08, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder
August 07, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Spray’s Potential Antidepressant Activity via Peripheral Nasal Neurons without Entry into the Brain
July 17, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease
July 13, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close